79.91
1.76 (2.25%)
| Previous Close | 78.15 |
| Open | 78.07 |
| Volume | 2,665,465 |
| Avg. Volume (3M) | 2,533,067 |
| Market Cap | 15,399,362,560 |
| Price / Sales | 42.13 |
| 52 Weeks Range | |
| Earnings Date | 19 Feb 2026 |
| Operating Margin (TTM) | -89.00% |
| Diluted EPS (TTM) | -3.56 |
| Quarterly Revenue Growth (YOY) | -44.80% |
| Current Ratio (MRQ) | 4.57 |
| Operating Cash Flow (TTM) | -500.42 M |
| Levered Free Cash Flow (TTM) | -261.20 M |
| Return on Assets (TTM) | -48.27% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | BridgeBio Pharma, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | -1.5 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 0.5 |
| Average | -0.63 |
|
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 4.97% |
| % Held by Institutions | 98.14% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Aisling Capital Management Lp | 30 Sep 2025 | 6,089,611 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 96.00 (Morgan Stanley, 20.14%) | Buy |
| Median | 86.00 (7.62%) | |
| Low | 77.00 (JP Morgan, -3.64%) | Buy |
| Average | 86.71 (8.51%) | |
| Total | 7 Buy | |
| Avg. Price @ Call | 73.27 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Barclays | 28 Jan 2026 | 80.00 (0.11%) | Buy | 77.49 |
| Wells Fargo | 20 Jan 2026 | 88.00 (10.12%) | Buy | 77.19 |
| 11 Nov 2025 | 84.00 (5.12%) | Buy | 66.58 | |
| Truist Securities | 08 Jan 2026 | 86.00 (7.62%) | Buy | 73.82 |
| Morgan Stanley | 06 Jan 2026 | 96.00 (20.14%) | Buy | 73.99 |
| Leerink Partners | 15 Dec 2025 | 86.00 (7.62%) | Buy | 74.51 |
| Bernstein | 11 Dec 2025 | 94.00 (17.63%) | Buy | 74.07 |
| JP Morgan | 07 Nov 2025 | 77.00 (-3.64%) | Buy | 61.80 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |